Bank of Montreal
CRSP icon

Bank of Montreal’s CRISPR Therapeutics CRSP Stock Holding History

Bank of Montreal’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-183,000
Closed -$11.9M – 3642
2025
Q3 		$11.9M Hold
183,000
– – ﹤0.01% 978
2025
Q2 		$8.9M Buy
+183,000
New +$7.08M ﹤0.01% 1031
2020
Q1 		– Sell
-7,600
Closed -$463K – 4201
2019
Q4 		$463K Hold
7,600
– – ﹤0.01% 2714
2019
Q3 		$312K Hold
7,600
– – ﹤0.01% 2673
2019
Q2 		$358K Buy
+7,600
New +$304K ﹤0.01% 2617

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bank of Montreal's CRSP Position: Q2 2026 in Review

Bank of Montreal increased its CRISPR Therapeutics (CRSP) stake by 3.5% in Q2 2026, buying an estimated $15.5K and bringing the position to 8,658 shares worth $472K. The position accounts for ﹤0.01% of the portfolio, ranked #2493.

Bank of Montreal first reported a position in CRSP in Q1 2017 and has held it in 34 quarters since. The position peaked at $24M in Q2 2025. 405 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Bank of Montreal held 8,658 shares of CRISPR Therapeutics worth $472K as of Q2 2026.
  • Bank of Montreal bought 295 CRISPR Therapeutics shares in Q2 2026, an estimated $15.5K.
  • CRISPR Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #2493 holding.
  • Bank of Montreal first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 34 quarters since.
  • Bank of Montreal's CRISPR Therapeutics position peaked at $24M in Q2 2025.
  • 405 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.